Pediatric medulloblastomas exhibit heterogeneous symptoms and varying responses to therapy, leading to poor outcomes in cases of tumor progression and incomplete resection. Early prediction of treatment responsiveness and applicability of immunotherapy has the potential to improve clinical management and outcomes.
Get the Latest
news, articles, and resources sent to your inbox.